May 29 |
Down -64.16% in 4 Weeks, Here's Why AEON Biopharma, Inc. (AEON) Looks Ripe for a Turnaround
|
May 29 |
AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan
|
May 15 |
AEON Biopharma, Inc. GAAP EPS of -$3.17
|
May 14 |
AEON Biopharma Reports First Quarter 2024 Financial Results
|
May 9 |
AEON Biopharma, Inc. (AEON) Loses -79.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
|
May 9 |
AEON Biopharma Provides Update on Development Pipeline
|
May 3 |
US Equity Markets Close Higher Friday Following Weak Jobs Report
|
May 3 |
Newly Listed Migraine-Focused AEON Biopharma Stock Plunges On Friday - Read Here Why
|
May 3 |
AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine
|
Apr 19 |
Here's Why AEON Biopharma, Inc. (AEON) Is a Great 'Buy the Bottom' Stock Now
|